WEBULL
WebtradeDownload

DENTSPLY SIRONA (XRAY) Stock Could Be Cheap As Sales Stay In Focus

Simply Wall St · 2d ago

DENTSPLY SIRONA has seen its share price fall sharply over recent years, yet the current valuation still rests on what investors are willing to pay for its sales base today. With the stock now trading at US$9.43, the key issue is whether that price is sensibly anchored to the revenue the business is generating.

  • Over the past 5 years, DENTSPLY SIRONA has declined 82%, which puts the focus squarely on whether the remaining market value is adequately supported by its sales.
  • The group’s position in dental equipment and consumables means future revenue can depend heavily on procedure volumes and dentist spending, which in turn may support or limit how much investors are prepared to pay for each dollar of sales.
  • The analysts covering DENTSPLY SIRONA have run their own numbers. See what analysts think DENTSPLY SIRONA's shares could be worth.

The stock’s next move may depend on whether the current share price is reasonably explained by the company’s sales when viewed against the Fair Ratio benchmark.

If you are weighing whether DENTSPLY SIRONA’s current price is justified by its sales, it can help to compare that question with a wider set of 28 high quality undervalued stocks

Does DENTSPLY SIRONA Look Undervalued on Sales?

The P/S ratio tends to suit DENTSPLY SIRONA because sales can be more stable than earnings for equipment suppliers during business resets or restructuring.

On this lens, the shares trade on a P/S of 0.5x, which is well below the Medical Equipment industry average of 2.7x and under the 4.0x peer group level. The tailored Fair Ratio, which adjusts for factors like size, margins and risk, sits higher than where the stock currently trades. As a result, the present multiple implies a discount to what that framework suggests might be reasonable for this type of business. For readers, the gap raises the question of whether the market is pricing in ongoing pressure on dental spending or structural challenges in DENTSPLY SIRONA’s product mix, or whether sentiment has simply turned too cautious relative to its revenue base. Explore the numbers behind DENTSPLY SIRONA's P/S valuation.

NasdaqGS:XRAY P/S Ratio as at Oct 2026
NasdaqGS:XRAY P/S Ratio as at Oct 2026

The DENTSPLY SIRONA Narrative: What Would Justify Today's Price?

Narratives pick up where the P/S puzzle leaves off for DENTSPLY SIRONA by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Each one sets out a fair value as a thesis about the business that can be revisited over time, so you can see how the underlying idea holds up as new information arrives.

Community views on DENTSPLY SIRONA are split between those who see quiet resilience and those who think recent setbacks already cap the upside.

Bull case: 79% undervalued

"One of XRAY’s strengths is its consumables portfolio, products that practices reorder regularly regardless of capital spending cycles…"

Discover why this Narrative puts DENTSPLY SIRONA at 79% undervalued.

Bear case: roughly fairly valued

"Although DENTSPLY SIRONA is investing more in R&D and clinical education under its 24 month Return to Growth Action Plan, the company has yet to show that these higher costs can reverse an average 5.7% constant currency revenue decline over the last two years…"

Explore why this Narrative puts DENTSPLY SIRONA at roughly fairly valued.

The share price is only one piece of the DENTSPLY SIRONA puzzle

Price tells you what the market thinks today, but analyst models sketch out where they expect DENTSPLY SIRONA to be a few years from now. This gives you another reference point to test your own view. Explore where analysts expect DENTSPLY SIRONA to be in a few years.